Talecris Biotherapeutics Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

October 7, 2009 4:05 PM EDT

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) ("Talecris" or the "Company") today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share. In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 6,000,000 shares of common stock from the selling stockholder, Talecris Holdings, LLC. Talecris Holdings LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and by limited partnerships affiliated with Ampersand Ventures. As a result, a total of 56,000,000 shares were sold in the initial public offering, consisting of 28,947,368 shares by the Company and 27,052,632 shares by the selling stockholder. Net proceeds received by the Company were used to pay down debt. The Company did not receive any proceeds from the sale of shares by the selling stockholder.

Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. acted as joint book-running managers for the offering. Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS Investment Bank acted as co-managers. Reed Smith LLP acted as legal counsel to Talecris.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 30, 2009. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any such offer or solicitation or any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the final prospectus for the offering may be obtained by contacting: Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014, telephone 1-866-718-1649 or by emailing prospectus@morganstanley.com; Goldman, Sachs & Co., Prospectus Department, 85 Broad Street, New York, New York 10004, telephone 1-866-471-2526, facsimile 1-212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, telephone 1-800-831-9146; or J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention: Prospectus Department, telephone 718-242-8002.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology and hemostasis.

    Source: Talecris Biotherapeutics Holdings Corp.

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• UBS
• Cerberus Capital
• JPMorgan
• Citi
• Morgan Stanley
• Barclays

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?